The new vaccine is an updated version of Moderna's widely-use Spikevax vaccine, which includes sequences from the original Wuhan strain of SARS-CoV-2, as well as from the Omicron BA.1 subvariant.

According to the lawsuit, the development of Moderna’s COVID-19 vaccine, Spikevax, depended on key technological advancements made at Northwestern. Also Read: Alnylam’s Concedes Its Patent ...

The booster shot – called mRNA-1273.211 – offered better and longer-lasting protection compared to the original SpikeVax shot against all SARS-CoV-2 variants, including the prevailing Omicron ...

The lawsuit said, opens new tab Moderna uses Northwestern-developed lipid nanoparticle (LNP) technology without a license in Spikevax shots to transport fragile messenger RNA into the human body.

The lawsuits specifically concern Moderna’s COVID-19 vaccine, Spikevax, and its more recently approved mRNA shot for respiratory syncytial virus (RSV), mRESVIA. GSK claims Moderna is marketing ...

This is a major concern for Moderna because it could mean that they used a GSK technology to produce their COVID-19 vaccine, Spikevax, as well as their RSV vaccine, mResvia. GSK asserts that ...

While 2024 has been a quiet year by the standards of Netflix’s programming, October has an embarrassment of riches when it comes to original series. Nobody Wants This has been a breakout hit ...

According to Reuters, the company earned $6.7 billion in revenue from Spikevax in 2023. Moderna has stated in the past that it is “not aware of any significant intellectual property impediments ...

The company exceeded expectations with its Spikevax revenue, notably due to an earlier approval that allowed for a rapid uptake in retail channels. This success drove Moderna’s Q3 sales to $1.8 ...

The Massachusetts-based company said that third-quarter revenue from its Spikevax shot came in at $1.8 billion, with $1.2 billion of the sales coming in the United States. The overall figure ...

Besides Sanofi deal for nuvaxovid, Novavax has few opportunities to generate additional revenue, which likely means its stock ...

Netflix is starting to pick up the pace of its original movies again as 2024 winds down. The problem is that not all of them deserve to be counted among the very best. Netflix has always favored ...